Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer

被引：11
|
作者：
Gonzalez, Nadia Saoudi [1 ,2 ]
Ros, Javier [1 ,2 ]
Baraibar, Iosune [1 ,2 ]
Salva, Francesc [1 ,2 ]
Rodriguez-Castells, Marta [1 ,2 ]
Alcaraz, Adriana [1 ,2 ]
Garcia, Ariadna [1 ]
Tabernero, Josep [1 ,2 ]
Elez, Elena [1 ,2 ]
机构：
[1] Vall dHebron Inst Oncol VHIO, Barcelona 08035, Spain
[2] Vall dHebron Hosp Campus, Barcelona 08035, Spain
来源：
CANCERS | 2024年 / 16卷 / 02期
关键词：
cetuximab; colorectal cancer; KRASG12C; BRAFV600; personalized treatment; RAS WILD-TYPE; PHASE-1; DOSE-ESCALATION; PLUS CETUXIMAB; OPEN-LABEL; SINGLE-AGENT; SOLID TUMORS; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; SUBGROUP ANALYSES; RANDOMIZED-TRIAL;
D O I：
10.3390/cancers16020412
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cetuximab, a chimeric IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has revolutionized personalized treatment of metastatic colorectal cancer (mCRC) patients. This review highlights the mechanism of action, characteristics, and optimal indications for cetuximab in mCRC. Cetuximab has emerged as a pivotal partner for novel therapies in specific molecular subgroups, including BRAF V600E, KRAS G12C, and HER2-altered mCRC. Combining cetuximab with immunotherapy and other targeted agents further expands the therapeutic landscape, offering renewed hope for mCRC patients who face the development of resistance to conventional therapies. Ongoing clinical trials have continued to uncover innovative cetuximab-based treatment strategies, promising a brighter future for mCRC patients. This review provides a comprehensive overview of cetuximab's role and its evolving importance in personalized targeted therapy of mCRC patients, offering valuable insights into the evolving landscape of colorectal cancer treatment.
引用
收藏
页数：18
相关论文
共 50 条
  • [1] Targeted therapy for metastatic colorectal cancer
    Price, Timothy J.
    Tang, Monica
    Gibbs, Peter
    Haller, Daniel G.
    Peeters, Marc
    Arnold, Dirk
    Segelov, Eva
    Roy, Amitesh
    Tebbutt, Niall
    Pavlakis, Nick
    Karapetis, Chris
    Burge, Matthew
    Shapiro, Jeremy
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (10) : 991 - 1006
  • [2] Therapy with cetuximab and irinotecan in refractory metastatic colorectal cancer
    Nature Clinical Practice Oncology, 2008, 5 (9): : 497 - 498
  • [3] The Economics of Personalized Therapy in Metastatic Colorectal Cancer
    Jain, Shweta
    Shankaran, Veena
    CURRENT COLORECTAL CANCER REPORTS, 2016, 12 (03) : 123 - 129
  • [4] Cetuximab for Metastatic Colorectal Cancer
    Roila, Fausto
    Garassino, Marina Chiara
    Ballatori, Enzo
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (01): : 95 - 95
  • [5] Cetuximab in metastatic colorectal cancer
    Broadbridge, Vy Tuong
    Karapetis, Cristos S.
    Price, Timothy Jay
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (05) : 555 - 565
  • [6] Cetuximab for metastatic colorectal cancer
    Sharma, Sharan Prakash
    LANCET ONCOLOGY, 2007, 8 (08): : 673 - 673
  • [7] Cetuximab in metastatic colorectal cancer
    Wolf, Ido
    Golan, Talia
    Shani, Adi
    Aderka, Dan
    LANCET ONCOLOGY, 2010, 11 (04): : 313 - 314
  • [8] Role of targeted therapy in metastatic colorectal cancer
    Yoshihito Ohhara
    Naoki Fukuda
    Satoshi Takeuchi
    Rio Honma
    Yasushi Shimizu
    Ichiro Kinoshita
    Hirotoshi Dosaka--Akita
    World Journal of Gastrointestinal Oncology, 2016, (09) : 642 - 655
  • [9] Cetuximab therapy in the treatment of metastatic colorectal cancer: The future frontier?
    Gomez, D.
    De Rosa, A.
    Addison, A.
    Brooks, A.
    Malik, H. Z.
    Cameron, I. C.
    INTERNATIONAL JOURNAL OF SURGERY, 2013, 11 (07) : 507 - 513
  • [10] Current Targeted Therapy for Metastatic Colorectal Cancer
    Ohishi, Tomokazu
    Kaneko, Mika K.
    Yoshida, Yukihiro
    Takashima, Atsuo
    Kato, Yukinari
    Kawada, Manabu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (02)
12345